Understanding Dual Therapy for Diabetic Eye Disease

Dual therapy in diabetic retinopathy (DR) and diabetic macular edema (DME) represents a strategic approach that combines two distinct treatment modalities—such as pairing anti-vascular endothelial growth factor (anti-VEGF) agents with laser photocoagulation, intravitreal corticosteroids, or systemic therapies—to simultaneously target different disease pathways. While monotherapy with anti-VEGF agents remains the first-line standard for most patients, dual therapy has gained increasing attention for individuals with persistent, recalcitrant, or complex disease who fail to achieve adequate anatomical and functional control with a single treatment modality alone.

The rationale behind this approach rests on the multifactorial nature of diabetic eye disease. Chronic hyperglycemia triggers a cascade of metabolic, hemodynamic, and inflammatory changes that cannot be fully addressed by blocking VEGF alone. By engaging complementary mechanisms, dual therapy may overcome compensatory upregulation of alternative angiogenic factors, reduce treatment burden, and improve long-term outcomes for selected patients.

The Pathophysiology Driving Combination Strategies

Diabetic eye disease originates from sustained hyperglycemia that disrupts the delicate balance of retinal homeostasis. Vascular endothelial growth factor (VEGF) is a primary driver of angiogenesis and vascular permeability, but it is not the only mediator at play. Pro-inflammatory cytokines such as interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), placental growth factor (PlGF), and reactive oxygen species all contribute to macular edema, capillary dropout, and neovascularization. Corticosteroids suppress many of these inflammatory pathways broadly, while laser photocoagulation reduces retinal oxygen demand, promotes reabsorption of subretinal fluid, and stabilizes the blood-retinal barrier.

Anti-VEGF agents themselves have distinct pharmacokinetic profiles. Aflibercept and brolucizumab offer higher binding affinity and longer duration of action than ranibizumab or bevacizumab. Adding a second modality such as laser or a corticosteroid can compensate for the shorter half-life of certain agents, extending treatment intervals and reducing injection frequency—a critical consideration for patients who struggle with frequent visits and for healthcare systems managing resource constraints.

Historical Context and Evolving Practice

Before the anti-VEGF era, laser photocoagulation was the mainstay of treatment for both DME and proliferative DR (PDR). The landmark DRCR.net Protocol I study demonstrated that ranibizumab combined with prompt laser achieved faster reduction in central macular thickness (CMT) than ranibizumab alone, although visual outcomes at one year were comparable. Subsequent trials, including RESTORE, RELIGHT, and BEVORDEX, reinforced the potential of combination therapy to reduce retreatment frequency while maintaining visual gains. The evolution from a laser-first approach to anti-VEGF-first, and now to selective dual therapy, reflects a maturing understanding of the biological complexity underlying diabetic eye disease and the need for personalized treatment algorithms.

Current Guidelines for Dual Therapy Use

Major professional organizations—including the American Academy of Ophthalmology (AAO), the European Society of Retina Specialists (EURETINA), and the International Council of Ophthalmology—have issued consensus recommendations that position dual therapy as a reserved strategy for specific clinical scenarios rather than a universal first-line approach. The AAO Preferred Practice Pattern for Diabetic Retinopathy (2023) explicitly states that combination therapy may be considered when there is insufficient response to anti-VEGF monotherapy, particularly in eyes with subretinal fluid or a significant inflammatory component.

Indications Based on Disease Presentation

Clinical guidelines identify several scenarios where dual therapy is appropriate:

  • Persistent DME after 3–6 monthly anti-VEGF injections: Defined as less than 20% reduction in CMT or no meaningful visual improvement. Adding focal or grid laser photocoagulation or an intravitreal corticosteroid (dexamethasone or fluocinolone acetonide implant) is recommended.
  • Recalcitrant DME with prominent inflammatory features: Eyes with subretinal fluid, dense hard exudates, cystoid changes, or a history of uveitis often reflect an inflammatory phenotype. Corticosteroids are particularly beneficial in this context, and guidelines suggest considering a switch after 3–4 anti-VEGF injections if response is suboptimal.
  • High-risk PDR with active neovascularization: Combination of panretinal photocoagulation (PRP) with anti-VEGF can accelerate regression of neovascularization and reduce the risk of vitreous hemorrhage, especially in patients with poor compliance or aggressive disease.
  • Injection burden intolerance: Patients requiring more than 6 injections per year may benefit from adding a sustained-release corticosteroid implant (Ozurdex or Iluvien) to extend treatment intervals to 3–6 months while maintaining disease control.

Contraindications and Safety Considerations

Combination therapy with corticosteroids carries well-documented risks: elevated intraocular pressure (IOP) and accelerated cataract formation. Patients with pre-existing glaucoma, ocular hypertension, or a family history of glaucoma require careful baseline evaluation and frequent IOP monitoring. Active ocular infection, uncontrolled systemic infection, or advanced media opacity are contraindications to intravitreal injections. Laser therapy near the fovea may cause paracentral scotomas, although modern navigated laser systems and micropulse laser technology have substantially reduced this risk. Systemic anticoagulation or antiplatelet therapy is not an absolute contraindication but demands caution to minimize hemorrhagic complications.

Evidence-Based Recommendations for Clinical Practice

Implementing dual therapy successfully requires a systematic approach grounded in evidence and tailored to individual patient characteristics. The following recommendations synthesize findings from major clinical trials and expert consensus guidelines.

Comprehensive Baseline Assessment

Before initiating dual therapy, a thorough baseline evaluation is essential to guide decision-making and establish benchmarks for monitoring:

  • Visual function testing: Best-corrected visual acuity (BCVA) using ETDRS or Snellen chart, and contrast sensitivity when available.
  • Ocular imaging: Spectral-domain OCT (SD-OCT) to quantify CMT, characterize intraretinal versus subretinal fluid, and identify vitreomacular traction. OCT angiography (OCTA) provides non-invasive assessment of the foveal avascular zone and areas of non-perfusion or neovascularization.
  • Fluorescein angiography (FA): Useful for mapping leakage, ischemia, and active neovascularization, particularly when laser therapy is being considered.
  • IOP measurement and gonioscopy: Essential if corticosteroids are planned, to rule out undiagnosed angle abnormalities.
  • Lens status: Phakic patients should receive counseling about cataract risk associated with corticosteroid use.
  • Systemic risk factor optimization: Hemoglobin A1c, blood pressure, serum lipids, and renal function must be assessed and managed. Optimal diabetes control and management of hypertension and hyperlipidemia are mandatory to maximize treatment outcomes and reduce disease progression.

Selecting the Appropriate Combination Modality

The choice of a second treatment modality should be guided by the clinical phenotype and patient priorities:

  • Predominantly angiogenic pattern: Eyes with active neovascularization, macular leakage on FA, and relatively thin retina are best suited for adding targeted focal or grid laser to anti-VEGF. Studies show that laser can reduce the need for subsequent injections by 30–40%.
  • Predominantly inflammatory pattern: Eyes with cystoid macular edema, thick retina, dense hard exudates, or a history of prior vitrectomy or uveitis respond well to corticosteroid implants. The BEVORDEX trial demonstrated that dexamethasone implant achieved comparable vision gains to ranibizumab with fewer injections, though rescue laser was more frequently required.
  • Mixed or uncertain phenotype: A stepwise approach is reasonable—initiate monotherapy for 3–4 injections, then reassess. If CMT remains above 300 µm or BCVA below 20/40, consider adding laser. If prominent cystoid changes persist, switch to a corticosteroid.
  • High injection burden: For patients requiring more than 8 injections annually, a sustained-release corticosteroid can dramatically reduce visit frequency. Fluocinolone acetonide (Iluvien) provides coverage for up to 3 years but carries higher risks of IOP elevation and cataract formation.

Timing and Sequence of Interventions

Two primary strategies have been studied:

  • Simultaneous dual therapy: Administering anti-VEGF injection followed by same-session laser. This approach offers convenience and cost-effectiveness, and data suggest faster anatomical improvement. It is particularly useful in PDR where rapid regression of neovascularization is desired.
  • Sequential dual therapy: Starting with anti-VEGF injections and adding laser or corticosteroid after 3–6 treatments if response is inadequate. This stepwise strategy minimizes overtreatment and identifies patients who respond well to monotherapy.

Most guidelines recommend initial monotherapy for 3–6 months. However, in eyes with very thick CMT (above 400 µm) or high-risk PDR, some experts advocate upfront combination. The DRCR.net Protocol I data showed that ranibizumab plus prompt laser reduced CMT faster, but visual gains at one year were similar between groups. Individualized clinical judgment remains essential.

Structured Monitoring and Follow-Up

After initiating dual therapy, a rigorous follow-up schedule is critical for safety and efficacy:

  • Monthly visits for the first 3 months, including BCVA, IOP, and SD-OCT.
  • After stabilization, transition to every 2–3 month visits. For patients receiving corticosteroid implants, IOP should be checked at 1 week, 1 month, and then monthly for 3 months post-injection.
  • If IOP rises more than 5 mmHg from baseline, initiate topical glaucoma therapy. If IOP exceeds 30 mmHg despite medications, consider removing the implant or converting to a non-steroid regimen.
  • Perform FA or OCTA if new neovascularization or worsening edema is suspected.
  • Re-evaluate the need for dual therapy every 6 months. If disease remains quiescent for 6–12 months, consider de-escalation to monotherapy or extended treatment intervals.

Patient Education and Shared Decision-Making

Effective communication is a cornerstone of successful dual therapy. Patients must understand the rationale for adding a second treatment—faster improvement, longer intervals between injections, improved anatomical outcomes—and the potential trade-offs, including IOP elevation, cataract formation, and post-laser scotomas. Using visual aids such as OCT images helps patients grasp why a second agent is needed. Shared decision-making tools allow patients to prioritize their preferences: for instance, a patient who values fewer injections may accept higher cataract risk, while a patient concerned about IOP may prefer adding laser over steroids. Encourage adherence to follow-up visits and emphasize the importance of systemic diabetes and blood pressure control as part of comprehensive disease management.

Emerging Evidence and Future Directions

The landscape of dual therapy continues to evolve rapidly with new pharmacologic agents, novel delivery systems, and biomarker-driven approaches that promise to refine patient selection and treatment protocols.

Novel Combination Strategies on the Horizon

Several emerging therapies and delivery platforms are reshaping the possibilities for dual therapy:

  • Brolucizumab plus laser: Brolucizumab offers high potency and extended durability, reducing injection frequency. Early data suggest that adding targeted laser to brolucizumab in PDR may further reduce retreatment rates and improve regression of neovascularization.
  • Faricimab: As the first bispecific antibody targeting both VEGF-A and angiopoietin-2 (Ang-2), faricimab has shown in phase 3 trials (YOSEMITE, RHINE) that monotherapy can achieve 12-week dosing intervals. Adding laser may extend intervals further or enhance outcomes in DME.
  • Suprachoroidal corticosteroid delivery: The suprachoroidal space allows targeted delivery of corticosteroids such as triamcinolone acetonide via the SCS Microinjector, with lower systemic absorption and potentially fewer IOP spikes. Combination with anti-VEGF is under investigation in the SCORE2 trial for DME.
  • Systemic fenofibrate: The FIELD and ACCORD studies demonstrated that fenofibrate reduces progression of DR. While not an ocular dual therapy per se, adding fenofibrate to intravitreal injections may provide synergistic retinoprotective benefits.

Biomarkers and the Path to Personalized Medicine

Identifying which patients will derive the greatest benefit from dual therapy is an active area of investigation. OCT biomarkers such as the presence of hyperreflective foci, subretinal fluid, and ellipsoid zone disruption have been shown to predict corticosteroid response. Genetic polymorphisms in VEGFR2, IL-6, and CFH may influence treatment outcomes. Machine learning algorithms analyzing baseline OCT images can now predict, with moderate accuracy, whether a patient will require dual therapy within the first year of treatment. These tools will enable clinicians to tailor therapy from the outset rather than relying on a trial-and-error approach, reducing the burden of suboptimal treatment on both patients and healthcare systems.

Long-Term Safety and Cost-Effectiveness Data

Long-term outcomes from the DRCR.net Protocol I study showed no increased risk of endophthalmitis or systemic adverse events with combination therapy over five years of follow-up, and patients in the ranibizumab-plus-laser group received fewer injections over time. Real-world studies confirm that sustained-release corticosteroid implants reduce injection frequency, visit burden, and cumulative drug costs. Health-economic analyses from the United Kingdom and United States report that combination therapy is cost-effective for patients requiring more than 6 injections annually, particularly when quality-adjusted life years (QALYs) are considered. However, long-term data on risks such as IOP-related glaucoma surgery or advanced cataract extraction with repeated corticosteroid use continue to be collected and will refine future recommendations.

Conclusion

Dual therapy offers a powerful treatment option for patients with diabetic eye disease who do not achieve adequate control with monotherapy. By leveraging complementary mechanisms of action, clinicians can achieve more robust and durable improvements in macular anatomy and visual function while potentially reducing treatment frequency and burden. Current guidelines from the AAO and EURETINA provide a practical framework for patient selection, reserving dual therapy for persistent DME, high-risk PDR, and cases of injection burden intolerance. Successful implementation requires thorough baseline assessment, careful selection of the combination modality based on clinical phenotype, structured monitoring for side effects, and active patient involvement in shared decision-making. As emerging therapies and biomarker-driven algorithms become integrated into clinical practice, the role of dual therapy will continue to expand, moving toward a more personalized and sustainable approach to managing this leading cause of preventable blindness. Clinicians are encouraged to stay current with ongoing trials and real-world evidence to optimize outcomes for their patients.

For further reading, consult the American Academy of Ophthalmology Preferred Practice Pattern for Diabetic Retinopathy, the National Eye Institute Diabetic Retinopathy resource, and the DRCR.net Protocol I long-term outcomes. Additional guidelines are available from the European Society of Retina Specialists and the American Diabetes Association. For detailed results from the BEVORDEX trial, see this publication.